EVIDENCE REQUIREMENTS FOR REIMBURSEMENT OF PHARMACEUTICALS ACROSS EUROPE
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
WMCLAHRC-2014-1
Department of Health - United Kingdom
PubMed
26168803
DOI
10.1017/s0266462315000227
PII: S0266462315000227
Knihovny.cz E-zdroje
- Klíčová slova
- Biomedical technology, Delivery of health care, Health policy, Reimbursement mechanisms, Technology assessment, biomedical,
- MeSH
- analýza nákladů a výnosů MeSH
- hodnocení biomedicínských technologií metody normy MeSH
- léky na předpis * MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
- Názvy látek
- léky na předpis * MeSH
OBJECTIVES: The objective of this study was to compare evidence requirements for health technology assessment of pharmaceuticals by national agencies across Europe responsible for reimbursement decisions focusing specifically on relative effectiveness assessment. METHODS: Evidence requirements from thirty-three European countries were requested and twenty-nine national agencies provided documents to review. Data were extracted from national documents (manufacturer's submission templates and associated guidance) into a purpose-made framework with categories covering information about the health condition, the technology, clinical effectiveness and safety. RESULTS: The level of detail in the required evidence varies considerably across countries. Some countries include specific questions while others request information under general headings. Some countries include all information in a single document, which may or may not include guidance on how to complete the template. Others have specific guidance documents or methods and process manuals that help with the completion of the submission templates. Despite differences in quantity and detail, the content of the evidence requirements is broadly similar. All countries ask for information on the health technology, target disease, and clinical effectiveness and safety. However, one country only requests clinical effectiveness information as part of cost-effectiveness analyses. We found twenty-six evidence requirements for which generic answers may apply across borders and nineteen in which countries requested nationally specific information. CONCLUSIONS: This work suggests that it would be possible to put together a minimum set of evidence requirements for HTA to support reimbursement decisions across Europe which could facilitate collaboration between jurisdictions.
Clinical and Health Psychology ZorgInstituut Nederland
Ministry of Health of the Czech Republic
National Institute for Health and Care
National Institute for Health and Care Excellence
National Institute for Quality and Organizational Development in HealthCare and Medicine
Citace poskytuje Crossref.org
